NextGen 2024: Unmet Needs & Clinical Trial Challenges Session Part 2

NextGen 2024: Unmet Needs & Clinical Trial Challenges Session Part 2

@SJIA_Foundation
@SJIA_Foundation
8 Followers
2 weeks ago 72

NextGen 2024: Unmet Needs & Clinical Trial Challenges Session Part 2

@SJIA_Foundation2 weeks ago

Clinical Trials in Still´s disease (sJIA/AOSD)
Fabrizio de Benedetti
Rheumatology, Children Hospi…
1/11
Clinical trials in Still‘s disease
Present scenario
•IL-1 or IL-6 inhibitors are very efficacious…
2/11
Clinical trials in Still‘s disease
Present scenario
•IL-1 or IL-6 inhibitors are very efficacious…
3/11
Refractory (D2T) Still‘s disease
•Persistent chronic arthritis (with or without active syst featur…
4/11
Refractory (D2T) Still‘s disease
1. persistent chronic arthritis (with or without active systemic …
5/11
Refractory (D2T) Still‘s disease
1. persistent chronic arthritis (with or without active systemic …
6/11
Refractory (D2T) Still‘s disease
2. Relapsing/smouldering MAS with or without LD
Syst features - …
7/11
Refractory (D2T) Still‘s disease
2. Relapsing/smouldering MAS with or without LD
Syst features - …
8/11
Refractory (D2T) Still‘s disease
2. Relapsing/smouldering MAS with or without LD
Syst features - …
9/11
Refractory (D2T) Still‘s disease
3. Acute MAS flare (with or without LD)
Classification criteria …
10/11
Refractory (D2T) Still‘s disease
3. Acute MAS flare (with or without LD)
Classification criteria …
11/11


  • Previous
  • Next
  • f Fullscreen
  • esc Exit Fullscreen
@SJIA_Foundation

Share

NextGen 2024: Unmet Needs & Clinical Trial Challenges Session Part 2

Embed code


Swipe LEFT
to view Related

Scroll DOWN
to read doc

This website uses cookies to improve your experience. By using this site, you consent to the use of cookies.

Login

OR

Forgot password?

Don't have an account? Sign Up